J&J Submits FDA Application for Myasthenia Gravis Drug Nipocalimab
These Are the Stocks With the Largest Changes in Short Interest in July - GS
Denali Therapeutics Analyst Ratings
Reported Earlier, Avidity Biosciences Prices $300.1M Upsized Public Offering Of 7,320,000 Common Stock At $41/Share
Denali Therapeutics Announces Publication In 'Science Translational Medicine' Demonstrating The Potential Of The OTV Platform To Achieve Broad Biodistribution Of Antisense Oligonucleotides In The CNS And Skeletal And Cardiac Muscle Following IV...
Avidity Biosciences Shares Are Trading Lower After the Company Proposed a $250 Million Public Offering of Common Stock.
Avidity Biosciences Analyst Ratings
The Analyst Landscape: 7 Takes On Avidity Biosciences
Evercore ISI Group Maintains Outperform on Avidity Biosciences, Raises Price Target to $54
Krystal Biotech Analyst Ratings
Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today
Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday
A Closer Look at 11 Analyst Recommendations For Crinetics Pharmaceuticals
Arcellx Analyst Ratings
Avidity Biosciences Says Data Suggest Del-zota Has Potential To Change Treatment Paradigm And Course Of Disease For Patients With Duchenne Muscular Dystrophy Mutations Amenable To Exon 44 Skipping
Arcellx GAAP EPS of -$0.51, Revenue of $27.38M
Needham Reiterates Hold on Amicus Therapeutics
Amicus Therapeutics Analyst Ratings
Crinetics Pharmaceuticals GAAP EPS of -$0.94 Misses by $0.09, Revenue of $0.39M Misses by $0.08M
Amicus Therapeutics Non-GAAP EPS of $0.06 Beats by $0.04, Revenue of $126.67M Beats by $5.43M